Publication at Faculty of Medicine in Pilsen |
2021
Abstract
Application of recombinant growth factors of erythropoiesis, resp. erythropoietins, resp. Erythropoiesis-Stimulating Agents (ESAs), in addition to transfusions of erythrocyte resuspensions, represent one of the ways to deal with anemia, not only in oncology.
The availability of mobilizable iron for erythropoiesis is an important prerequisite for the effect of ESA treatment and iron substitution p.o. or i.v. iron must be given in good time if necessary.